Edit |   |
Antigenic Specificity | mTOR |
Clone | polyclonal |
Host Species | Rabbit |
Reactive Species | human, mouse, rat |
Isotype | n/a |
Format | affinity purified |
Size | 0.1 mL, 0.2 mL |
Concentration | n/a |
Applications | Western Blot (WB), Immunohistochemistry (IHC) |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | The mammalian target of rapamycin (mTOR, FRAP, RAFT) is a Ser/Thr protein kinase (1-3) that functions as an ATP and amino acid sensor to balance nutrient availability and cell growth (4,5). When sufficient nutrients are available, mTOR responds to a phosphatidic acidmediated signal to transmit a positive signal to p70 S6 kinase and participate in the inactivation of the eIF4E inhibitor, 4E-BP1 (6). These events result in the translation of specific mRNA subpopulations. mTOR is phosphorylated at Ser2448 via the PI3 kinase/Akt signaling pathway and autophosphorylated at Ser2481 (7,8). mTOR plays a key role in cell growth and homeostasis and may be abnormally regulated in tumors. For these reasons, mTOR is currently under investigation as a po |
Immunogen | Immunogen: A synthetic -peptide of human mTOR |
Other Names | [MTOR; FLJ44809; FRAP; FRAP2; MTOR; RAFT1; RAPT1;], [MTOR; MTOR; FRAP; FRAP1; FRAP2; RAFT1; RAPT1; FRAP; FRAP1; FRAP2; RAFT1; RAPT1; mTOR] |
Gene, Accession # | Gene ID: 2475, NCBI: NP_004949.1, UniProt: P42345 |
Catalog # | MBS125585 |
Price | $275, $430 |
Order / More Info | mTOR Antibody from MYBIOSOURCE INC. |
Product Specific References | 1. Sabers, C.J. et al. (1995) J Biol Chem 270, 815-22. 2. Brown, E.J. et al. (1994) Nature 369, 756-8. 3. Sabatini, D.M. et al. (1994) Cell 78, 35-43. 4. Gingras, A.C. et al. (2001) Genes Dev 15, 8072-6. 5. Dennis, P.B. et al. (2001) Science 294, 1102-5. 6. Fang, Y. et al. (2001) Science 294, 1942-5. 7. Nave, B.T. et al. (1999) Biochem J 344 Pt 2, 427-31. 8. Peterson, R.T. et al. (2000) J Biol Chem 275, 7416-23. 9. Huang, S. and Houghton, P.J. (2003) Curr Opin Pharmacol 3, 371-7 |